|
Davis
M. NEI sponsored clinical studies for
CMV retinitis (SOCA). Presented to the
American Academy of Ophthalmology,
Anaheim, CA, October 1991.
Studies
of Ocular Complications of AIDS Research
Group in Collaboration with the National
Eye Institute. FGCRT - Mortality
results. Press conference, October 1991.
Meinert
C. SOCA CMV retinitis trial mortality
results. Presented to the FDA Antiviral
Advisory Board, Washington, DC, November
1991.
Jabs
DA. Foscarnet vs. Ganciclovir as initial
treatment of CMV retinitis. Presented to
the NIH AIDS Program Advisory Committee,
Bethesda, MD, November 1991.
Jabs
DA. Results from SOCA study: Foscarnet-Ganciclovir
CMV Retinitis Trial. Presented to the
AIDS Clinical Trials Group, Washington,
DC, December 1991.
Mowery
R. SOCA study, an update. Presented to
the National Advisory Eye Council,
Washington DC, February 1992.
Back
to TOP
of page
Meinert
C. Mortality in patients with AIDS
treated with either foscarnet or
ganciclovir for CMV retinitis: results
from a randomized trial. Presented to
the European AIDS conference, Paris,
France, March 1992.
Jabs
DA for the Studies of Ocular
Complications of AIDS Research Group:
Foscarnet-Ganciclovir Cytomegalovirus
Retinitis Trial: Mortality results.
Presented to the VIII International AIDS
Conference/III STD World Congress,
Amsterdam, The Netherlands, July 1992.
Wu
AW, Coleson LC, Holbrook JT, Jabs DA: A
questionnaire to measure visual function
and quality of life in CMV retinitis.
Presented to IX International AIDS
Conference, Berlin, Germany, June 1993.
Holbrook
JT, Jabs DA, Jacobson MA, Mendez P, Min
Y, Murphy R: Foscarnet-related
abnormalities in serum creatinine,
calcium, and magnesium in patients with
CMV retinitis. Presented to IX
International AIDS Conference, Berlin,
Germany, June 1993.
Meinert
CL for SOCA Research group. HPMPC
Peripheral CMV Retinitis Trial:
Preliminary Treatment Results. Presented
to FDA Antiviral Advisory Committee,
Gaithersburg, MD, March 1996.
Jacobson
MA, Drew WL, Dunn JP, Feinberg J,
Holbrook J, Martin B, Min N, Murphy R.
Foscarnet-ganciclovir CMV Retinitis
Trial: CMV culture results and clinical
outcomes in AIDS patients with CMV
retinitis treated with either foscarnet
or ganciclovir. Presented to XI
International AIDS Conference,
Vancouver, BC, July 1996.
Lawrence
DW, Jacobson MA, Dunn JP, Feinberg J,
Holbrook J, Martin B, Min N, Murphy R.
Incidence of drug resistant CMV culture
isolates and association with clinical
outcomes in AIDS patients with CMV
retinitis treated with either foscarnet
(PFA) or ganciclovir (GCV). Presented to
XI International AIDS Conference,
Vancouver, BC, July 1996.
Holbrook
J, Davis M, Gilpin AK, Hubbard L, Martin
B. Association of Cytomegalovirus (CMV)
retinitis characteristics with disease
progression and vision loss. Presented
to XI International AIDS Conference,
Vancouver, BC, July 1996.
Dietrich
D for the SOCA Research Group.
Monoclonal Antibody CMV Retinitis Trial:
Preliminary results. Presented to the
36th Interscience Conference on
Antimicrobial Agents and Chemotherapy,
New Orleans, LA, September 1996.
Back
to TOP
of page
Wu
AW for the SOCA Research Group. Clinical
trials: Future study design and
methodology. Issues of concern to
patients - Quality of life. Presented to
the California Intercampus Ophthalmology
Symposium, San Francisco, CA, February 1997.
Jabs
DA for the SOCA Research Group.
Cidofovir (HPMPC) for the treatment of
CMV retinitis: The HPMPC Peripheral CMV
Retinitis Trial. Presented to the Macula
Society Meeting, Florence, Italy, June 1997.
Wu
AW for the SOCA Research Group.
Reliability, validity and responsiveness
of patient - reported health and vision
measures in AIDS-related CMV retinitis.
Presented to the Drug Information
Association, January 1998.
Meinert
CL for the SOCA Research group.
Reliability, validity and responsiveness
of subjective measures of health status
and vision in patients with AIDS and CMV
retinitis. Presented to the Association
for Research in Vision and
Ophthalmology, Fort Lauderdale, Fl, May 1998.
Wu
AW for the SOCA Research Group. The
importance of patient reported vision in
CMV retinitis. Presented at Yosemite,
California, February, 1999.
Martin
B for the SOCA Research Group. Effect of
CMV retinitis treatment on patient -
reported and objective measures of
vision. Presented to the International
Society for Quality of Life Research,
November 1998.
Martin
B for the SOCA Research Group.
Evaluating Disease - specific Quality of
Life Measures in a Clinical Trial for
Cytomegalovirus Retinitis. Presented to
the Epidemiology Department, Baltimore,
MD, March 1999.
Back
to TOP
of page
Van
Natta M and Min Y. Bias in
"as-treated" analysis using
time-varying treatment. Presented to the
Society for Clinical Trials, Controlled
Clinical Trials -
21(25):1335, 2000.
Holbrook
JT, Meinert CL, VanNatta ML, Davis M,
Hubbard L, Jabs DA, for the SOCA
Research Group. Photographic measures of
cytomegalovirus retinitis as surrogates
for visual outcomes in treated patients.
Presented to the Society for Clinical
Trials. Controlled Clinical
Trials 21(25):825, 2000.
Davidson
M, Min Y, Holbrook JT, Van Natta M, Jabs
DA, Murphy R, Welch W, Meinert CL for
the SOCA Research Group. Influence of
Granulocyte Colony Stimulating Factor
(G-CSF) Use on Bacterial Infections and
Mortality in Advance AIDS. Presented to
the XIII International AIDS Conference,
Durban, South Africa, July 2000.
Min
YI, Davidson M, Holbrook JT, VanNatta M,
Jabs DA, Murphy R, Welch W, Meinert CL
for the SOCA Research Group, Granulocyte
colony-stimulating factor (G-CSF) use
and mortality in patients with AIDS and
CMV retinitis. Presented to the 5th
International Conference on Drug Therapy
in HIV Infection. AIDS 14(54):576. 2000.
Davidson
M, Min YI, Holbrook JT, Quinn TC, Murphy
R, Jabs DA, Welch W, Meinert CL for the
SOCA Research Group. The influence of
granulocyte colony-stimulating factor on
HIV-1 RNA in patient with CMV retinitis.
Presented to the 5th International
Conference on Drug Therapy in HIV
Infection. AIDS 14(54):575, 2000.
Holbrook
JT. Closeout Procedures for Clinical
Trials. Workshop at Society for Clinical
Trial 22nd Annual Meeting Controlled
Clinical Trials. 22(25): 225, 2001.
Kempen JH, Martin BK, Wu AW, Barron
B, Thorne JE, Jabs DA for The Studies of
Ocular Complications of AIDS Research
Group. The Impact of Cytomegalovirus
Retinitis on the Quality of Life of
Patients with the Acquired Immune
Deficiency Syndrome. Presented at the
Association for Research in Vision and
Ophthalmology, May, 2003.
Jabs DA, Holbrook JT, Van Natta ML,
Clark R, Jacobson MA, Kempen JH, Murphy
RL for the SOCA Research Group, Risk
Factors for Mortality in Patients with
AIDS in the Era of Highly Active
Antiretroviral Therapy*. Presented
at Annual meeting of the American
Academy of Ophthalmology, October,
2005.
Click Link to Mortality paper slide
presentation, presented by D Jabs at
Research Group meeting (Sept 2005, San
Diego CA) *Selected for Editors'
Choices Symposium, AAO, October 2005.
Back
to TOP
of page
|
